These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21195724)

  • 1. Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway.
    Luo Q; Gu Y; Zheng W; Wu X; Gong F; Gu L; Sun Y; Xu Q
    Toxicol Appl Pharmacol; 2011 Mar; 251(2):130-6. PubMed ID: 21195724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Jaceosidin inhibits contact hypersensitivity in mice via down-regulating IFN-γ/STAT1/T-bet signaling in T cells.
    Yin Y; Sun Y; Gu L; Zheng W; Gong F; Wu X; Shen Y; Xu Q
    Eur J Pharmacol; 2011 Jan; 651(1-3):205-11. PubMed ID: 21093428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the immunosuppressive activity of artemether on T-cell activation and proliferation.
    Wang JX; Tang W; Shi LP; Wan J; Zhou R; Ni J; Fu YF; Yang YF; Li Y; Zuo JP
    Br J Pharmacol; 2007 Mar; 150(5):652-61. PubMed ID: 17262016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
    Wang Z; Wang M; Carr BI
    J Cell Physiol; 2005 Jun; 203(3):510-9. PubMed ID: 15534860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway.
    Li LB; Goleva E; Hall CF; Ou LS; Leung DY
    J Allergy Clin Immunol; 2004 Nov; 114(5):1059-69. PubMed ID: 15536411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaticaffinol, a resveratrol tetramer, exerts more preferable immunosuppressive activity than its precursor in vitro and in vivo through multiple aspects against activated T lymphocytes.
    Feng LL; Wu XF; Liu HL; Guo WJ; Luo Q; Tao FF; Ge HM; Shen Y; Tan RX; Xu Q; Sun Y
    Toxicol Appl Pharmacol; 2013 Mar; 267(2):167-73. PubMed ID: 23276654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo.
    Wang JX; Tang W; Yang ZS; Wan J; Shi LP; Zhang Y; Zhou R; Ni J; Hou LF; Zhou Y; He PL; Yang YF; Li Y; Zuo JP
    Eur J Pharmacol; 2007 Jun; 564(1-3):211-8. PubMed ID: 17349993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
    Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway.
    Tu CT; Li J; Wang FP; Li L; Wang JY; Jiang W
    Int Immunopharmacol; 2012 Dec; 14(4):410-21. PubMed ID: 22940540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partially purified components of Nardostachys chinensis suppress melanin synthesis through ERK and Akt signaling pathway with cAMP down-regulation in B16F10 cells.
    Jang JY; Kim HN; Kim YR; Choi WY; Choi YH; Shin HK; Choi BT
    J Ethnopharmacol; 2011 Oct; 137(3):1207-14. PubMed ID: 21816215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
    Wang J; Zhao Y; Kauss MA; Spindel S; Lian H
    Eur J Cell Biol; 2009 Feb; 88(2):103-15. PubMed ID: 19058874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
    Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
    Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.